CY1116724T1 - SALINOSPORAMIDES AND METHODS OF USE - Google Patents

SALINOSPORAMIDES AND METHODS OF USE

Info

Publication number
CY1116724T1
CY1116724T1 CY20151100744T CY151100744T CY1116724T1 CY 1116724 T1 CY1116724 T1 CY 1116724T1 CY 20151100744 T CY20151100744 T CY 20151100744T CY 151100744 T CY151100744 T CY 151100744T CY 1116724 T1 CY1116724 T1 CY 1116724T1
Authority
CY
Cyprus
Prior art keywords
cnb476
cnb392
salinosporamides
marine
strains
Prior art date
Application number
CY20151100744T
Other languages
Greek (el)
Inventor
William H Fenical
Paul R Jensen
Tracy J Mincer
Robert H R Feling
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/600,854 external-priority patent/US7179834B2/en
Priority claimed from US10/838,157 external-priority patent/US7176232B2/en
Priority claimed from EP11163737.7A external-priority patent/EP2441767B1/en
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of CY1116724T1 publication Critical patent/CY1116724T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Η παρούσα εφεύρεση βασίζεται στην ανακάλυψη ότι ορισμένα προϊόντα ζύμωσης των θαλάσσιων στελεχών ακτινομύκητα CNB392 και CNB476 λειτουργούν ως αποτελεσματικοί αναστολείς υποπολλαπλασιαστικών κυττάρων θηλαστικού. Τα στελέχη CNB392 και CNB476 ανήκουν στην οικογένεια των Micromonosporaceae, και το γενικό επίθετο Salinospora έχει προταθεί για αυτήν την υποχρεωτικά θαλάσσια ομάδα. Τα προϊόντα αντίδρασης που παράγονται από αυτό το στέλεχος ταξινομούνται ως σαλινοσποραμίδες, και είναι ιδιαιτέρως επωφελή στη θεραπευτική αγωγή νεοπλαστικών διαταραχών λόγω του χαμηλού μοριακού βάρους, των χαμηλών τιμών IC50, της υψηλής φαρμακευτικής ισχύος, και της εκλεκτικότητας αυτών για καρκινικά κύτταρα έναντι μυκήτων.The present invention is based on the discovery that certain fermented products of the marine strains CNB392 and CNB476 function as effective inhibitors of mammalian proliferative cells. The CNB392 and CNB476 strains belong to the family of Micromonosporaceae, and the generic adjective Salinospora has been proposed for this obligatory marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in the treatment of neoplastic disorders due to their low molecular weight, low IC50 values, high drug potency, and their selectivity for cancer cells.

CY20151100744T 2003-06-20 2015-08-25 SALINOSPORAMIDES AND METHODS OF USE CY1116724T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/600,854 US7179834B2 (en) 2002-06-24 2003-06-20 Salinosporamides and methods for use thereof
US10/838,157 US7176232B2 (en) 2002-06-24 2004-04-30 Salinosporamides and methods for use thereof
EP11163737.7A EP2441767B1 (en) 2003-06-20 2004-06-18 Salinosporamides and methods for use thereof

Publications (1)

Publication Number Publication Date
CY1116724T1 true CY1116724T1 (en) 2017-03-15

Family

ID=46713688

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100744T CY1116724T1 (en) 2003-06-20 2015-08-25 SALINOSPORAMIDES AND METHODS OF USE

Country Status (8)

Country Link
KR (1) KR101315595B1 (en)
CY (1) CY1116724T1 (en)
DK (1) DK2441767T3 (en)
ES (1) ES2546415T3 (en)
IL (1) IL240236B (en)
MX (1) MX361003B (en)
PT (1) PT2441767E (en)
SI (1) SI2441767T1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144723B2 (en) 2000-11-16 2006-12-05 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product discovery

Also Published As

Publication number Publication date
ES2546415T3 (en) 2015-09-23
DK2441767T3 (en) 2015-08-24
KR101315595B1 (en) 2013-10-08
IL240236B (en) 2021-02-28
SI2441767T1 (en) 2015-10-30
MX361003B (en) 2018-11-23
PT2441767E (en) 2015-10-09
KR20120081637A (en) 2012-07-19
IL240236A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
MXPA05013985A (en) Salinosporamides and methods for use thereof.
CY1117417T1 (en) PROTAGLAND NITROXYPER PRODUCTS
AR122771A2 (en) ANTIBODIES FOR THE TREATMENT OF CANCER, CONJUGATED, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID AND HOST CELL
CY1119563T1 (en) OPTIMIZATION OF ANTIBODIES Binding to Lymphocyte Activation Gene-3 (LAG-3), AND USES THEREOF
CY1119002T1 (en) ANSWERS TO POLYETHERINE DESPHERTHIOCIN
CY1118303T1 (en) SPECIFICATION FOR CROSS-CUTTING SINGLE SPECIAL SINGLE-SINGLE ANTIBODY PSMAXCD3
DE60126483D1 (en) TARGETED MODIFICATION OF THE CHROMATIN STRUCTURE
MX2010005334A (en) Inhibitors of human immunodeficiency virus replication.
CY1114340T1 (en) COMPOSITIONS AND USES FOR TREATMENT TREATMENT
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
PT1411908E (en) TREATMENT OF INFECTIONS OF THE
EP1483281A4 (en) Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
AU2003263552A1 (en) Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EA201000470A1 (en) BIOLOGICAL OILS, THEIR OBTAINING AND USE
CO5611065A2 (en) DIFLUOROMETILTIAZOLILCARBOXANILIDAS
BRPI0414599A (en) substituted pyrrol indoles
EA200801462A1 (en) BINDING DNA SITE OF TRANSCRIPTION ACTIVATOR SUITABLE FOR GENE EXPRESSION
CY1108549T1 (en) SYNTHETIC METHODS FOR APLIDIN AND NEW VOLUME PRODUCERS, METHODS OF CONSTRUCTION AND USE
CY1119779T1 (en) PEGYLIOMH L-ASPARAGINATION
EA200501162A1 (en) Pyrazolilcarboxanilides to combat unwanted microorganisms
PL1877367T3 (en) Acetylene derivatives
ES2335410T8 (en) DERIVATIVES OF AMINOPROPANOL.
GB0216002D0 (en) Process and composition
EA200870158A1 (en) HIV TREATMENT
EA200600778A1 (en) 1,3-DIMETHYLBUTYLKARBOXANILES TO COMBAT AGAINST UNDESIRABLE MICROORANISMS